title: A review of monoclonal antibody therapies in lymphoma.
abstract: Monoclonal antibodies (moAb) represent a novel way of delivering therapy through specific target antigens expressed on lymphoma cells and minimizes the collateral damage that is common with conventional chemotherapy. The paradigm of this approach is the targeting of CD20 by rituximab. Since its FDA approval in 1997, rituximab has become the standard of care in almost every line of therapy in most B-cell lymphomas. This review will briefly highlight some of the key rituximab trials while looking more closely at the evidence that is bringing other antibodies, including next generation anti-CD20 moAbs, and anti-CD30 moAbs, among others to the forefront of lymphoma therapy.
authors: Department of Hematology, Singapore General Hospital, Singapore.
authors: Esmeralda Chi-yuan
authors: EC
authors: Teo
authors: Medifast Medical Centre, Singapore.
authors: Yveline
authors: Y
authors: Chew
authors: Department of Hematology, Singapore General Hospital, Singapore; DUKE-NUS Graduate Medical School, Singapore. Electronic address: colin.phipps.diong@sgh.com.sg.
authors: Colin
authors: C
authors: Phipps
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000079963:Brentuximab Vedotin; D051925:CD79 Antigens / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D000069283:Rituximab / Q000627:therapeutic use; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000037:antagonists & inhibitors / Q000276:immunology; D059470:Tetraspanins / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000951:Antigens, Neoplasm; C059071:CD37 protein, human; D051925:CD79 Antigens; D018796:Immunoconjugates; D051918:Sialic Acid Binding Ig-like Lectin 2; D059470:Tetraspanins; D000074323:Alemtuzumab; D000069283:Rituximab; D000079963:Brentuximab Vedotin
keywords: Antibody-conjugates; Lymphoma; Monoclonal antibodies; Targeted therapy